"Moderna's RSV Vaccine Efficacy Decline Sparks Stock Slide"
TL;DR
Moderna's shares dropped 7% as analysts expressed concerns over the faster decline in efficacy of its RSV vaccine compared to competitors GSK and Pfizer, with data showing a drop from 84% to 63% after 8.6 months. Moderna cautioned against direct comparisons, citing different trial methodologies, but analysts raised questions about the competitive profile of its vaccine. GSK and Pfizer's vaccines also showed declines in efficacy over time, with both companies exploring the possibility of at least two years of efficacy.
- Moderna shares slide on concerns over drop in RSV vaccine efficacy Yahoo Finance
- Moderna's RSV shot efficacy wanes faster than GSK's Arexvy FierceBiotech
- Moderna (MRNA) Stock Falls After RSV Vaccine Data Showing Waning Efficacy Bloomberg
- Readout Newsletter: Moderna, Metagenomi, Gritstone, etc STAT
- Moderna’s RSV Vaccine May Lose Efficacy Faster Than GSK and Pfizer’s Barron's
Want the full story? Read the original reporting
Read on Yahoo Finance